Vermillion to Report First Quarter 2016 Financial Results and Host Investor Conference Call on May 16

AUSTIN, Texas, May 2, 2016 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its first quarter 2016 financial results on Monday, May 16, 2016, followed by an investor conference call and webcast at 4:30pm Eastern.

About VermillionVermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women conquer serious diseases.  The company's initial in vitro diagnostic test, OVA1®, was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016 Vermillion received FDA clearance for Overa™, a second generation OVA1 with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.

Investor Relations Contact:Michael WoodLifeSci Advisors LLCTel 1-646-597-6983[email protected]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vermillion-to-report-first-quarter-2016-financial-results-and-host-investor-conference-call-on-may-16-300260980.html

SOURCE Vermillion, Inc.